MINERVA BIOTECHNOLOGIES

Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Its stem cell technology could transform the field of regenerative medicine. It discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. It is also the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate and are more easily directed to develop into functional mature cells, which could be used for transplant. It was founded in 1999 and is headquartered in Waltham, Massachusetts.